Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03642522
Other study ID # H14-02819
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2018
Est. completion date August 1, 2020

Study information

Verified date January 2021
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression. These biomarkers include simultaneous TMS-fMRI (functional magnetic resonance imaging), a blood smear, cognitive and behavioural assessments, questionnaires, and neurophysiology.


Description:

This study is enrolling 60 individuals with treatment-resistant depression. All patients will receive four weeks of 1-Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC). In addition, all patients will undergo baseline and post-treatment measures, including rTMS while they are in the MRI scanner, neurophysiology (Electroencephalography (EEG)/Near-Infrared Spectroscopy (NIRS)), cognitive testing, behavioural assessments and a blood smear. There will also be a 1-week, 4-week, and 12-week follow-up following completion of the treatment course.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date August 1, 2020
Est. primary completion date March 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility TRD Patient Inclusion Criteria: Patients will be included if they: 1. are outpatients 2. are voluntary and competent to consent to treatment 3. have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of MDD, single or recurrent 4. are between the ages of 18 and 80 years 5. have failed to achieve a clinical response to at least one adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of score = 3 in the current episode OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF 1 or 2) 6. have a score = 22 on the IDS item 7. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to initiation of rTMS 8. able to adhere to the treatment schedule 9. pass the TMS adult safety screening (TASS) questionnaire First Episode Depression Inclusion Criteria: Patients will be included if they: 1. are outpatients 2. are voluntary and competent to consent to treatment 3. have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of MDD, single or recurrent 4. are between the ages of 18 and 80 years 5. have never received and adequate antidepressant trial and are not currently taking any antidepressant. 6. have a score = 12 on the IDS item 7. are on no psychotropic medication for the 4 weeks prior to initiation of rTMS, with the exception of lorazepam up to 2mg or equivalent dose of benzodiazepine or prescribed sleeping aids including (zopiclone up to 15mg/d, zolpidem up to 10mg/d). 8. able to adhere to the treatment schedule 9. pass the TMS adult safety screening (TASS) questionnaire Patient Exclusion Criteria: Patients are excluded if they: 1. have a history of substance dependence or abuse within the last 3 months 2. have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump 3. have active suicidal intent 4. are pregnant 5. have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms 6. have a MINI diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD 7. have a diagnosis of any personality disorder, and assessed by a study investigator to be primary and causing greater impairment than MDD 8. have failed a course of ECT in the current episode or previous episode 9. have received rTMS for any previous indication due to the potential compromise of expectancy effects 10. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than 5 minutes 11. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed 12. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study 13. have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators 14. are currently (or in the last 4 weeks) taking lorazepam greater than 2 mg daily (or equivalent) or any dose of an anticonvulsant, due to the potential to limit rTMS efficacy 15. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview). 16. have failed more than 5 adequate trials of medication in the current episode. 17. Exclusion criteria for MRI: Those with a history of cranial, thoracic or abdominal surgery, with pacemakers, artificial joins or other metallic implants will be excluded from the MRI scan. Subjects that have agreed to participate in the MRI portion of the study will be pre- screened for any potential metal fragments in the body (particularly in the orbits) if they have had any history of doing metal work or have been involved in use/deployment of ammunitions/explosives, welding, piping etc.). In these cases a CT scan will be performed prior to the MRI scan ---------- Healthy Control Inclusion Criteria Participants will be included if they: 1. are voluntary and competent to consent to the study 2. are between the ages of 18 and 80 3. are fluent in English, sufficient to complete interviews and cognitive testing 4. have no history of Axis I or Axis II disorders, as determined by the MINI 5. pass the TMS adult safety screening (TASS) questionnaire Healthy Control Exclusion Criteria: Participants will be excluded if they: 1. have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms 2. have a MINI diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), dysthymia or any personality disorder 3. have history of bipolar disorder or psychosis in first degree relative (parents, siblings, offspring) 4. are unable to provide family history of biological family (i.e., adopted persons are not eligible) 5. have a history of substance dependence within the last 3 months 6. have a concomitant major unstable medical illness 7. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes 8. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview). 9. have a personal or family history of seizures 10. Exclusion criteria for MRI: Those with a history of cranial, thoracic or abdominal surgery, with pacemakers, artificial joins or other metallic implants will be excluded from the MRI scan. Those who are pregnant will also be excluded from the MRI scan. Subjects that have agreed to participate in the MRI portion of the study will be pre-screened for any potential metal fragments in the body (particularly in the orbits) if they have had any history of doing metal work or have been involved in use/deployment of ammunitions/explosives, welding, piping etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
repetitive transcranial magnetic stimulation
rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (= 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.

Locations

Country Name City State
Canada Non-Invasive Neurostimulation Therapies lab, University of British Columbia Vancouver British Columbia

Sponsors (2)

Lead Sponsor Collaborator
University of British Columbia University of Victoria

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Quick Inventory of Depressive Symptomatology (QIDS-SR) The quick inventory of depressive symptomatology is self-rated depression scale. Outcome will be total score. Minimum score is 0 and maximum score is 27. Higher scores indicate worse severity. 16 weeks
Other Inventory of Depressive Symptomatology (IDS-30) The quick inventory of depressive symptomatology is self-rated depression scale. Outcome will be total score. Minimum score is 0 and maximum score is 27. Higher scores indicate worse severity. 16 weeks
Other The Montgomery-Åsberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale is a clinician-rated depression scale. Outcome will be total score. Minimum score is 0 and maximum score is 60. Higher scores indicate worse severity. 4 weeks
Other The Montgomery-Åsberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale is a clinician-rated depression scale. Outcome will be total score. Minimum score is 0 and maximum score is 60. Higher scores indicate worse severity. 16 weeks
Primary Inventory of Depressive Symptomatology (IDS-30) The inventory of depressive symptomatology is a clinician-rated depression scale. Outcome will be total score. Minimum score is 0 and maximum score is 84. Higher scores indicate worse severity. 4 weeks
Secondary Quick Inventory of Depressive Symptomatology (QIDS-SR) The quick inventory of depressive symptomatology is self-rated depression scale. Outcome will be total score. Minimum score is 0 and maximum score is 27. Higher scores indicate worse severity. 4 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A